Loading...
Can treatment-experienced patients now achieve virologic suppression at rates comparable to those seen in patients new to therapy? The answer — based on this prospective study of darunavir, etravirine, and raltegravir combined — is an emphatic yes.
Multiclass treatment–experienced patients from 49 HIV clinics in France were eligible for enrollment if they had never received any of the three agents and had no evidence of either etravirine or darunavir resistance, based on genotypic criteria in use at the time. A total of 103 patients were enrolled, with a median therapy duration of 13 years, a median CD4 count of 255 cells/mm3, and a median viral load of 4.2 log copies/mL. Baseline resistance testing showed a median of six NRTI mutations, fou…